Production (Stage)
ZyVersa Therapeutics, Inc.
ZVSA
$0.54
-$0.0027-0.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 40.79% | 13.11% | 2.23% | 78.81% | -359.57% |
| Total Depreciation and Amortization | -558.82% | -83.65% | 300.00% | 102.29% | -195.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 76.17% | -1.11% | -47.68% | -97.43% | 7,980.78% |
| Change in Net Operating Assets | -104.90% | 135.63% | 153.57% | 9.78% | -182.45% |
| Cash from Operations | -90.04% | 66.33% | 49.32% | -35.49% | -197.67% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 267.21% | -- | -100.00% | -46.55% | 63.05% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | 100.00% |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -126.49% | -- | -- | -- | -18.84% |
| Cash from Financing | 306.39% | -- | -100.00% | -38.51% | 90.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 41,311.76% | 100.18% | -73.36% | -170.82% | 15.48% |